Outcomes at First Relapse for Patients with Multiple Myeloma who receive Triplet versus Quadruplet Induction Therapy Read more
MMRC Horizon One: A Phase II Randomized adaptive platform Trial evaluating novel therapies in relapsed or refractory multiple myeloma Read more
Real world experience with KCD-R management in patients with newly diagnosed Waldenstrom Macroglobulinemia Read more
Clinical Grade Molecular Profiling of Patients with Multiple Myeloma and Related Plasma Cell malignancies Read more
A Phase 2 Study of Erdafitinib in Patients with Recurrent or Progressive IDH-Wild Type Glioma with an FGFR-TACC Gene Fusion Read more
Characteristics and Outcomes of Patients with Multiple Myeloma Treated with Chimeric Antigen Receptor T Cell Therapy” Read more
Prognostic significance of cytogenetic abnormalities and molecular classification on mortality and morbidity at Hackensack Meridian Health in patients treated for multiple myeloma Read more
